Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Infections, Death Fail To Stop Novartis’ Phase III MS Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

“Confounding” factors in play; monitoring board gives green light to continue.
Advertisement

Related Content

Novartis Hedges Its Bet On Fingolimod In MS
Novartis Hedges Its Bet On Fingolimod In MS
Teva Pits Oral Laquinimod Against Avonex In MS Trial
Teva Pits Oral Laquinimod Against Avonex In MS Trial
Serono Taps Aussie Biotech For New MS Drugs
Serono Taps Aussie Biotech For New MS Drugs
Novartis’ Oral MS Drug Strong In Three-year Phase II Data
Novartis’ Oral MS Drug Strong In Three-year Phase II Data

Topics

Advertisement
UsernamePublicRestriction

Register

PS068029

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel